We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Advancing ALS Research With Omics Analysis Technology
Industry Insight

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Read More

Antibody To Treat Lung Inflammation May Offer Potential in COVID-19
Industry Insight

Early stage biotech company Aqualung Therapeutics is currently developing a therapeutic monoclonal antibody – ALT-100 – for the treatment of unchecked inflammation. COVID-19 can cause severe pneumonia and respiratory failure. There is therefore a potential option to treat patients diagnosed with COVID-19 with ALT-100. Technology Networks recently spoke with Joe Garcia, MD, Founder and Chief Executive Officer of Aqualung Therapeutics to learn more.

Read More

Development of Immunotherapy To Treat COVID-19 in Progress
Industry Insight

CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.

Read More

Harnessing the Immune System for Early Cancer Detection
Industry Insight

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

Read More

Going Label-Free: The Future of Metabolomics Imaging
Industry Insight

The study of brain tumors using real-time imaging of the brain in live disease models is critical for elucidating disease mechanisms and developing novel treatment strategies. Such research requires full characterization of healthy and disease phenotypes using a multi-omics analysis, as described in this blog.

Read More

Will the Potential of Proteomics Be Realized in 2020?
Industry Insight

Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.

Read More

Facilitating Cell Culture Growth and Protecting Protein Integrity
Industry Insight

Many biotherapeutic drugs such as recombinant antibodies are manufactured utilizing host cells, a common example being Chinese hamster ovary (CHO) cells. A key factor for consideration in this process is the growth and viability of these cells – ultimately this influences the quality and quantity of the biotherapeutic product. Technology Networks spoke with Nicole Wellens, Global Product Manager for BioTherapeutics Media, Lonza to learn more about the new feed and how it has been developed.

Read More

Delving Into Glycogen Storage Diseases
Industry Insight

In this interview, Gaia Fancellu, of Iceni Diagnostics, talks about her work in more detail, discusses the challenges of studying GSDs, and highlights the advantages of using a “Systems Medicine” approach to do so.

Read More

Releasing the Handbrake on Endogenous Repair – An Alternative Approach to Treating Alzheimer’s Disease?
Industry Insight

Technology Networks recently spoke with Paul Brennan, President and CEO at NervGen Pharma, to gain his insights on why previous attempts to treat Alzheimer's disease have failed, how the novel technology platform NVG-291 works and what promise it holds for AD.

Read More

Using Protein Biomarkers Increases the Chances of Success in Clinical Trials
Industry Insight

Many clinical trials fail due to lack of efficacy. But while some of this may be due to poor target selection during the drug discovery process, it’s becoming increasingly clear that only certain patients respond to treatments. So how exactly does precision medicine increase the likelihood of success in clinical trials?

Read More

 
Advertisement